EMA validates Type II variation application for Padcev with Keytruda for first line treatment of advanced Bladder Cancer: Pfizer Ruchika Sharma28 Jan 2024 10:00 AM ISTTokyo: Astellas Pharma Inc. and Pfizer Inc. have announced that the European Medicines Agency (EMA) has validated for review a Type II...
Merck bags USFDA nod for Keytruda, Padcev combo for urothelial cancer Ruchika Sharma18 Dec 2023 1:45 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA,...
Merck application for Keytruda plus Padcev for Urothelial Cancer gets USFDA priority review Ruchika Sharma2 Dec 2023 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has accepted...
Merck Keytruda plus Padcev improves survival in advanced or metastatic urothelial carcinoma Ruchika Sharma24 Sept 2023 3:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced positive topline results from the Phase 3 KEYNOTE-A39...
U S government sets penalties on 43 drugs over price hikes Ruchika Sharma11 Jun 2023 2:30 PM ISTThe Medicare agency plans to send the first invoices to drugmakers in 2025 for the rebates owed to Medicare this year and for 2024.
Merck gets USFDA nod for Keytruda in combination with Padcev to treat Advanced or Metastatic Urothelial Cancer Ruchika Sharma5 April 2023 1:16 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA,...
Merck secures USFDA priority review for PADCEV with KEYTRUDA for treatment of Urothelial Cancer Ruchika Sharma22 Dec 2022 3:21 PM ISTPADCEV (enfortumab vedotin-ejfv) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface...
